Slow Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Slow Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-19,331	Closed	-$1.7M	–	174
2020 Q4	$1.7M	Buy	19,331 +887	+5%	+$70.3K	0.41%	90
2020 Q3	$1.4M	Buy	18,444 +1,032	+6%	+$104K	0.38%	100
2020 Q2	$2.15M	Sell	17,412 -196	-1%	-$19.5K	0.63%	52
2020 Q1	$1.49M	Buy	17,608 +719	+4%	+$62K	0.56%	66
2019 Q4	$1.43M	Buy	+16,889	New	+$1.28M	0.44%	80
2019 Q3	–	Sell	-5,419	Closed	-$464K	–	167
2019 Q2	$464K	Sell	5,419 -1,729	-24%	-$148K	0.19%	129
2019 Q1	$635K	Buy	7,148 +170	+2%	+$15.8K	0.25%	116
2018 Q4	$594K	Buy	6,978 +1,610	+30%	+$153K	0.29%	107
2018 Q3	$521K	Buy	5,368 +226	+4%	+$22.6K	0.23%	117
2018 Q2	$484K	Sell	5,142 -1,323	-20%	-$116K	0.25%	111
2018 Q1	$524K	Sell	6,465 -438	-6%	-$37.6K	0.24%	115
2017 Q4	$615K	Buy	+6,903	New	+$600K	0.32%	98

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Slow Capital's BMRN Position: Q1 2021 in Review

Slow Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 19,331 shares — an estimated $1.7M sold.

Slow Capital first reported a position in BMRN in Q4 2017 and held it in 12 quarters. The position peaked at $2.15M in Q2 2020. 531 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

Slow Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Slow Capital sold 19,331 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $1.7M.
Slow Capital first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 12 quarters.
Slow Capital's BioMarin Pharmaceuticals position peaked at $2.15M in Q2 2020.
531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Slow Capital's 13F filing for Q1 2021, filed 5 May 2021.